臨床外科77巻7号

2022年07月発行

特集 徹底解説！ 食道胃接合部癌《最新版》

総論

食道胃接合部腺癌の薬物療法

著者： 中田晃暢¹ 室圭¹

所属機関： ¹愛知県がんセンター薬物療法部

ページ範囲：P.790 - P.798

文献概要

【ポイント】
◆食道胃接合部腺癌の薬物療法は，通常の胃体部腺癌に準じて実施されている．
◆進行胃腺癌・食道胃接合部腺癌の一次治療として，免疫チェックポイント阻害薬であるニボルマブが保険適用拡大となり，ニボルマブ併用化学療法が新たな標準治療となった．
◆自験例では，食道胃接合部腺癌と胃体部腺癌において，全身化学療法の生存期間に違いを認めなかった．

参考文献

1）西　満正：噴門癌について—食道胃境界部癌の提唱．外科診療15：1328-1338，1973

2）三隅厚信，馬場憲一郎，庄嶋　健，他：噴門癌の定義に関するわれわれの見解．胃と腸17：573-579，1982

3）三隅厚信，村上　明，原田　和，他：内視鏡と局所解剖（2）噴門．消内視鏡2：255-259，1990

4）Yamashita H, Seto Y, Sano T, et al：Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer 20（Suppl 1）： 69-83, 2017

5）日本胃癌学会（編）；胃癌治療ガイドライン医師用2021年　改訂第6版．金原出版，2021

6）Boku N, Yamamoto S, Fukuda H, et al：Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer：a randomised phase 3 study. Lancet Oncol 10：1063-1069, 2009

7）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 9：215-221, 2008

8）Cunningham D, Starling N, Rao S, et al：Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358：36-46, 2008

9）Ohtsu A, Shah M A, Van Cutsem E, et al：Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer：a randomized, double-blind, placebo-controlled phase Ⅲ study. J Clin Oncol 29：3968-3976, 2011

10）Yamada Y, Higuchi K, Nishikawa K, et al：Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 26：141-148, 2015

11）Bang Y J, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 376：687-697, 2010

12）Shah M A, Bang Y J, Lordick F, et al：Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma：the METGastric randomized clinical trial. JAMA Oncol 3：620-627, 2017

13）Boku N, Ryu MH, Oh DY, et al：LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction（G/GEJ）cancer：ATTRACTION-4（ONO-4538-37）study. Ann Oncol 31（Suppl）：S1192, 2020

14）Janjigian YY, Shitara K, Moehler M, et al：First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma（CheckMate 649）：a randomised, open-label, phase 3 trial. Lancet. 398：27-40, 2021

15）Janjigian YY, Bang Y-J, Fuchs CS, et al：KEYNOTE-811：pembrolizumab plus trastuzumab and chemotherapy for HER2＋ metastatic gastric or gastroesophageal junction cancer（mG/GEJC）：a double-blind, randomized, placebo-controlled phase 3 study. J Clin Oncol 37（15 suppl）：TPS4146-TPS4146, 2019

16）厚生労働省：最適使用推進ガイドライン—ニボルマブ（遺伝子組換え）〜胃癌〜，平成29年9月（令和3年11月改訂）．http://pmda.go.jp/files/000243693.pdf

17）Miura Y, Sukawa Y, Hironaka S, et al：Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer：a phase Ⅱ trial and biomarker study（WJOG7212G）. Gastric Cancer 21：84-95, 2018

18）Kurokawa Y, Sugimoto N, Miwa H, et al：Phase Ⅱ study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer（HERBIS-1）. Br J Cancer 110：1163-1168, 2014

19）Ryu MH, Yoo C, Kim JG, et al：Multicenter phase Ⅱ study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 51：482-488, 2015

20）Gong J, Liu T, Fan Q, et al：Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer（CGOG1001）：a multicenter, phase Ⅱ trial. BMC Cancer 16：68, 2016

21）Rivera F, Romero C, Jimenez-Fonseca P, et al：Phase Ⅱ study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer：HERXO trial. Cancer Chemother Pharmacol 83：1175-1181, 2019

22）Takahari D, Chin K, Ishizuka N, et al：Multicenter phase Ⅱ study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. Gastric Cancer 22：1238-1246, 2019

23）Yuki S, Shinozaki K, Kashiwada T, et al：Multicenter phase Ⅱ study of SOX plus trastuzumab for patients with HER2（＋） metastatic or recurrent gastric cancer：KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemother Pharmacol 85：217-223, 2020

24）Stagg J, Loi S, Divisekera U, et al：Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 108：7142-7147, 2011

25）Gall VA, Philips AV, Qiao N, et al：Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res 77：5374-5383, 2017

26）Thuss-Patience PC, Kretzschmar A, Bichev D, et al：Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie（AIO）. Eur J Cancer 47：2306-2314, 2011

27）Kang JH, Lee SI, Lim DH, et al：Salvage chemotherapy for pretreated gastric cancer：a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30：1513-1518, 2012

28）Ford HE, Marshall A, Bridgewater JA, et al：Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma（COUGAR-02）：an open-label, phase 3 randomised controlled trial. Lancet Oncol 15：78-86, 2014

29）Hironaka S, Ueda S, Yasui H, et al：Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum：WJOG 4007 trial. J Clin Oncol 31：4438-4444, 2013

30）Wilke H, Muro K, Van Cutsem E, et al：Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma（RAINBOW）：a double-blind, randomised phase 3 trial. Lancet Oncol 15：1224-1235, 2014

31）Shitara K, Özgüroğlu M, Bang Y J, et al：Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer（KEYNOTE-061）：a randomised, open-label, controlled, phase 3 trial. Lancet 392：123-133, 2018

32）Kang YK, Boku N, Satoh T, et al：Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens（ONO-4538-12, ATTRACTION-2）：a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390：2461-2471, 2017

33）Shitara K, Doi T, Dvorkin M, et al：Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer（TAGS）：a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19：1437-1448, 2018

34）Shitara K, Bang YJ, Iwasa S, et al：Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382：2419-2430, 2020